4552 — JCR Pharmaceuticals Share Price
Last trade - 00:00- ¥61bn
- ¥115bn
- ¥40bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 282.73 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -54.14% | ||
| Dividend Yield (f) | 4.01% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.49 | ||
| Price to Tang. Book | 1.58 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.57 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -6.38% | ||
| Return on Equity | -7.63% | ||
| Operating Margin | -8.97% | ||
Financial Summary
| Year End 31st Mar | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 51,082 | 34,343 | 42,871 | 33,072 | 40,319 | 45,370 | 43,267 | 6.03% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +126.7 | -75.36 | +44.78 | n/a | n/a | -77.66 | +9.1 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
JCR Pharmaceuticals Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. It manufactures, purchases, and sells prescription drugs, regenerative medicine products, and pharmaceutical raw materials. Through its subsidiaries, it is also engaged in purchasing business, procurement and sales of medical and research equipment, facility management, market research, management and supervision of outsourced clinical trial operations, management of intellectual property and licensing, clinical operations, regulatory affairs, and development in Brazil and Europe, and distribution management of pharmaceuticals and their raw materials.
Directors
- Shin Ashida FDR (83)
- Toru Ashida CHM (57)
- Yutaka Honda SME
- Takashi Suetsuna IND (77)
- Yuko Hayashi IND (61)
- Toshihiro Ishikiriyama SME (73)
- Hiroyuki Sonoda PRE (48)
- Yoshio Hiyama MEO (66)
- Yutaka Atomi IND (81)
- Marc Dunoyer IND (73)
- Yoh Ito MEO
- Andrea Spezzi SME (60)
- Makoto Ashida MEO
- Hiroyuki Fukutani CCO
- Toshio Asano IND (73)
- Last Annual
- March 31st, 2026
- Last Interim
- September 30th, 2026
- Incorporated
- September 13th, 1975
- Public Since
- March 16th, 1995
- No. of Shareholders
- 23,763
- No. of Employees
- 985
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 122,251,630
- Address
- 3-19, Kasuga-cho, ASHIYA-SHI, 659-0021
- Web
- https://www.jcrpharm.co.jp
- Phone
- +81 797328591
- Auditors
- Deloitte Touche Tohmatsu LLC
Latest News for 4552
Upcoming Events for 4552
Q3 2027 JCR Pharmaceuticals Co Ltd Earnings Release
Dividend For 4552.T - 10.0000 JPY
Similar to 4552
ASKA Pharmaceutical Holdings
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings
Tokyo Stock Exchange
CanBas
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
As of Today at 02:28 UTC, shares in JCR Pharmaceuticals are trading at ¥499. This share price information is delayed by 15 minutes.
Shares in JCR Pharmaceuticals last closed at ¥499 and the price had moved by -19.77% over the past 365 days. In terms of relative price strength the JCR Pharmaceuticals share price has underperformed the Nikkei 225 Index by -32.71% over the past year.
The overall consensus recommendation for JCR Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe JCR Pharmaceuticals dividend yield is 4.01% based on the trailing twelve month period.
Last year, JCR Pharmaceuticals paid a total dividend of ¥20, and it currently has a trailing dividend yield of 4.01%.Looking ahead, shares in JCR Pharmaceuticals are due to go ex-dividend on 2027-03-30 and the next dividend pay date is 2026-12-04.
JCR Pharmaceuticals are due to go ex-dividend on 2027-03-30 and the next dividend pay date is 2026-12-04. The historic dividend yield on JCR Pharmaceuticals shares is currently 4.01%.
To buy shares in JCR Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of ¥499, shares in JCR Pharmaceuticals had a market capitalisation of ¥61bn.
Here are the trading details for JCR Pharmaceuticals:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4552
Based on an overall assessment of its quality, value and momentum JCR Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in JCR Pharmaceuticals is ¥670. That is 34.27% above the last closing price of ¥499.
Analysts covering JCR Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of ¥2 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like JCR Pharmaceuticals. Over the past six months, its share price has underperformed the Nikkei 225 Index by -4.92%.
As of the last closing price of ¥499, shares in JCR Pharmaceuticals were trading -8.02% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The JCR Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 282.73. The shares last closed at ¥499.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
JCR Pharmaceuticals' management team is headed by:
- Shin Ashida - FDR
- Toru Ashida - CHM
- Yutaka Honda - SME
- Takashi Suetsuna - IND
- Yuko Hayashi - IND
- Toshihiro Ishikiriyama - SME
- Hiroyuki Sonoda - PRE
- Yoshio Hiyama - MEO
- Yutaka Atomi - IND
- Marc Dunoyer - IND
- Yoh Ito - MEO
- Andrea Spezzi - SME
- Makoto Ashida - MEO
- Hiroyuki Fukutani - CCO
- Toshio Asano - IND